Communiqués ImmuPharma plc

Actions

IMM

GB0033711010

Recherche biotechnologique et médicale

Marché Fermé - London S.E. 17:45:50 17/09/2026			Varia. 5j.	Varia. 1 janv.
3,980 ^GBX	+13,88%		+12,59%	-35,81%

16/09	RÉSULTATS ET ACTIVITÉ : Chiffre d'affaires en hausse pour Amcomri ; acquisition de Unicorn Namibia	AN
15/09	ImmuPharma plc publie ses résultats pour le semestre clos le 30 juin 2026	CI

Communiqués

22/07	ImmuPharma : selects Thermo Fisher Scientific drug product CDMO for Kapiglucagon program	PU
22/07	ImmuPharma : 2026 Result of Annual General Meeting	PU
25/06	ImmuPharma : appoints Bachem as API manufacturing partner for Kapiglucagon	PU
27/05	ImmuPharma : FINAL RESULTS for the twelve months ended 31 December 2025	PU
10/04	TR-1: Standard form for notification of major holdings	PU
24/11	ImmuPharma : Corporate Update	PU
04/11	ImmuPharma : TR1 from Lanstead – Major interest in shares	PU
13/10/25	ImmuPharma : Appointment of Independent Non-Executive Director	PU
07/10/25	ImmuPharma : TR1 from Lanstead – Major interest in shares	PU
20/08/25	ImmuPharma : TR1 from Lanstead Capital – Major interest in shares	PU
12/06/25	ImmuPharma : 2025 Result of Annual General Meeting	PU
28/05/25	ImmuPharma : TR1 from Lanstead – Major interest in shares	PU
19/05/25	ImmuPharma : Annual Report 2024	PU
19/05/25	ImmuPharma : FINAL RESULTS for the twelve months ended 31 December 2024	PU
22/02/25	ImmuPharma : TR1 from Lanstead – Major interest in shares	PU
08/01/25	Immupharma : at JP MORGAN CONFERENCE and BIOTECH SHOWCASE 11-16 January 2025, San Francisco	PU
04/12/24	ImmuPharma : Appointment of Company Secretary	PU
08/08/24	ImmuPharma : TR1 – Major Holding – Lanstead	PU
01/07/24	ImmuPharma : 2024 Result of Annual General Meeting – all resolutions passed	PU
05/06/24	ImmuPharma : Annual Report 2023	PU
05/06/24	ImmuPharma : FINAL RESULTS for the twelve months ended 31 December 2023	PU
26/03/24	ImmuPharma : Incanthera Provides Commercial Update and Revenue Forecasts	PU
08/03/24	ImmuPharma CEO Tim McCarthy discusses financial stability and promising drug developments	AQ
02/01/24	TR1 – Major Holding by Lanstead (Date: 28 December 2023)	PU
20/12/23	ImmuPharma : TR1 – Major holding by Lanstead	PU